Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Mirtazapine to Reduce Methamphetamine Use Among MSM With High-Risk HIV Behaviors
This study is currently recruiting participants.
Study NCT00497081 Information provided by National Institute on Drug Abuse (NIDA)
First Received: July 5, 2007 Last Updated: April 15, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Substance Abuse
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Infection
Substance-Related Disorders
More general conditions related to this trial
Disorders of Environmental Origin
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Mental Disorders
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
mirtazapine
Additional drug interventions recognized in this trial
Amphetamine
Methamphetamine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Uptake Inhibitors
Antidepressive Agents
Antidepressive Agents, Tricyclic
Autonomic Agents
Central Nervous System Agents
Central Nervous System Stimulants
Dopamine Agents
Dopamine Uptake Inhibitors
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sympathomimetics
Therapeutic Uses
Sponsors listed in this trial
National Institute on Drug Abuse (NIDA)
Back to top of Main Content
